Navigation Links
NuVasive Completes Acquisition of Osteocel Biologics Business
Date:7/24/2008

y do not materialize or prove correct, could cause Company's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that the Company's revenue or profitability projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that Company may encounter unanticipated difficulty integrating the Osteocel product into its product line; the risk that the Company may be unable to generate expected revenues or profitability from Osteocel; the uncertain process of seeking regulatory approval or clearance for Company's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to Company's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of Company's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in Company's press releases and periodic filings with the Securities and Exchange Commission. Company's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. Company assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

Nu
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
2. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
3. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
4. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
7. NuVasive to Host Investor Reception on September 11, 2007
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
10. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
11. Accuri Cytometers Completes $13 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  David Hardison, Ph.D., vice president of health ... been elected chairman of the board for the ... to establish common protocols around the use of ... electronic health records. Hardison will ... organizations across the research and health care arena ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
... I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
... 2010 Cardium Therapeutics (NYSE Amex: CXM ... and Chief Executive Officer will present at the LifeTech ... at 2:00 p.m. Eastern.  The conference will take place ... presentation will not be webcast, investors can access the ...
Cached Biology Technology:HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 2YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 4YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 5YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 6YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 7YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 8YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 9YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 10YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 11YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 12Cardium to Present at the LifeTech Capital Miami Medical Investors Conference 2
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
(Date:7/28/2014)... to map social connections in prairie dogs have ... light on prairie dog communities that may help ... future conservation efforts. The work was done by ... National Evolutionary Synthesis Center (NESCent). , "Prairie dogs ... plague," says Dr. Jennifer Verdolin, lead author of ...
(Date:7/27/2014)... species of mayfly in the southern Western Ghats, a mountain ... is the first time that any mayfly belonging to the ... , The new species, called Labiobaetis soldani , "is ... contribution to the understanding of the Ephemeroptera of Palaearctic and ... describes the new mayfly in the Journal of Insect ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Social network research may boost prairie dog conservation efforts 2
... combination of the biology of marine mammals, mechanical vibrations ... scientists to better understand the potential harmful effects of ... An international team of researchers from UC ... Zoo in Sweden has developed an approach that integrates ...
... 31, 2010 − A York University doctoral student who discovered ... lab one morning has completed a study that examines 84 ... including the one Jason Gibbs found in downtown Toronto ... identified or described before. Gibbs, expansive study will help ...
... brains, mouth bacteria behaving badly and the hundreds of ... some of the highlights at the Society for General ... annual event takes place on 6-9 September at the ... experts will present cutting-edge scientific research covering a wide ...
Cached Biology News:Researchers develop simulation to better understand the effects of sound on marine life 2Researchers develop simulation to better understand the effects of sound on marine life 3York U researcher finds new bee in downtown Toronto 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... 220-240 V, uses floating pin printing technology ... and other biomolecules onto a variety of ... generate high-density arrays with greater than 80,000 ... 57,000 spots per membrane with a capacity ...
... systems are high-precision microarrayers capable of ... samples. VersArray ChipWriter Pro systems set ... and reproducibility to deliver unparalleled quality ... Their modular component design and flexible ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: